The saponin D39 blocks dissociation of non-muscular myosin heavy chain IIA from TNF receptor 2, suppressing tissue factor expression and venous thrombosis

Br J Pharmacol. 2017 Sep;174(17):2818-2831. doi: 10.1111/bph.13885. Epub 2017 Jul 18.

Abstract

Background and purpose: Non-muscular myosin heavy chain IIA (NMMHC IIA) plays a key role in tissue factor expression and venous thrombosis. Natural products might inhibit thrombosis through effects on NMMHC IIA. Here, we have shown that a natural saponin, D39, from Liriope muscari exerted anti-thrombotic activity in vivo, by targeting NMMHC IIA.

Experimental approach: Expression and activity of tissue factor in endothelial cells were analysed in vitro by Western blot and simplified chromogenic assays. Interactions between D39 and NMMHC IIA were assessed by serial affinity chromatography and molecular docking analysis. D39-dependent interactions between NMMHC IIA and TNF receptor 2 (TNFR2) were measured by immunofluorescence, co-immunoprecipitation and proximity ligation assays. Anti-thrombotic activity of D39 in vivo was evaluated with a model of inferior vena cava ligation injury in mice.

Key results: D39 inhibited tissue factor expression and procoagulant activities in HUVECs and decreased thrombus weight in inferior vena cava-ligated mice dose-dependently. Serial affinity chromatography and molecular docking analysis suggested that D39 bound to NMMHC IIA. In HEK293T cells, D39 inhibited tissue factor expression evoked by NMMHC IIA overexpression. This effect was blocked by NMMHC IIA knockdown in HUVECs. D39 inhibited dissociation of NMMHC IIA from TNFR2, which subsequently modulated the Akt/GSK3β-NF-κB signalling pathways.

Conclusions and implications: D39 inhibited tissue factor expression and thrombus formation by modulating the Akt/GSK3β and NF-κB signalling pathways through NMMHC IIA. We identified a new natural product that targeted NMMHC IIA, as a potential treatment for thrombotic disorders and other vasculopathies.

MeSH terms

  • Animals
  • Cells, Cultured
  • Fibrinolytic Agents* / pharmacology
  • Fibrinolytic Agents* / therapeutic use
  • Glycogen Synthase Kinase 3 beta / metabolism
  • HEK293 Cells
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Male
  • Mice, Inbred C57BL
  • Molecular Docking Simulation
  • Myosin Heavy Chains / genetics
  • Myosin Heavy Chains / metabolism*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, Tumor Necrosis Factor, Type II / metabolism*
  • Saponins* / pharmacology
  • Saponins* / therapeutic use
  • Thromboplastin / metabolism*
  • Transcription Factor RelA / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology
  • Venous Thrombosis / blood
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / metabolism

Substances

  • Fibrinolytic Agents
  • Receptors, Tumor Necrosis Factor, Type II
  • Saponins
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Thromboplastin
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • Myosin Heavy Chains